The oral vaccine riding inside the good bacteria makes it way through the stomach and into the small intestine, an important immunological organ, where it easily and efficiently binds to cells that trigger an immune response – in this case, protection against anthrax in mice.
The finding, published the week of Feb. 16 in the online edition of Proceedings of the National Academy of Sciences, shows that an oral vaccine can be as effective as one given by needle, a potentially huge advance in drug delivery. Most vaccines are proteins, and as such normally won’t maintain their effectiveness after being digested in the stomach.
The good bacteria – Lactobacillus acidophilus, a lactic acid bacteria – are naturally found in dairy products like milk and cheese, and are added by manufacturers to foods like yogurt. They are used in food fermentationas, are safe for consumption and some are considered as probiotics that contribute to our general health and well being.
In the paper, Dr. Todd Klaenhammer, Distinguished University Professor and William Neal Reynolds Professor in the Department of Food, Bioprocessing and Nutrition Sciences, Dr. Tri Duong from the functional genomics program at NC State, and colleagues from the U.S. Army Medical Research Institute of Infectious Disease show that the acid tolerant lactic acid bacteria can act like an EZ Pass, delivering the anthrax vaccine through the stomach and releasing it into the small intestine.
There, the vaccine targets the first line of immune cells, dendritic cells, that can trigger the mucosal immune system to respond and elicit protection against anthrax. In the study, the oral vaccine worked about as well as a vaccine delivered by needle, the standard way of inoculating living things from viruses and pathogens.
“Normally, you can’t eat vaccines because the digestive process in the stomach destroys them, so vaccines are administered by needle,” Klaenhammer says. “But using ‘food grade’ lactic acid bacteria as a vehicle provides a safe way of getting the vaccine into the small intestine without losing any of the drug’s efficacy in binding to the dendritic cells, which can then trigger an immune response.”
Klaenhammer and his colleagues are now attempting to use lactic acid bacteria to carry varying types of oral vaccines to provide immunity to important viruses and pathogens. They are also working to improve the efficiency of binding of Lactobacillus acidophilus and the vaccine to dendritic cells.
“Can we make these generally recognized as safe lactic acid bacteria into a premier delivery system for vaccines and biotherapeutics? That’s the question we’re now trying to answer,” Klaenhammer says.
The study was funded by a grant from the National Institutes of Health and the North Carolina Dairy Foundation.
Note to editors: An abstract of the paper follows.“Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge”
Published: The week of Feb. 16, 2009, online in Proceedings of the National Academy of Sciences
Abstract: Efficient vaccines potentiate antibody avidity and increase T cell longevity, which confer protection against microbial lethal challenge. A vaccine strategy was established by using Lactobacillus acidophilus to deliver Bacillus anthracis protective antigen (PA) via specific dendritic cell-targeting peptides to dendritic cells (DCs), which reside in the periphery and mucosal surfaces, thus directing and regulating acquired immunity. The efficiency of oral delivery of L. acidophilus expressing a PA-DCpep fusion was evaluated in mice challenged with lethal B. anthracis Sterne. Vaccination with L. acidophilus expressing PA-DCpep induced robust protective immunity against B. anthracis Sterne compared with mice vaccinated with L. acidophilus expressing PA-control peptide or an empty vector. Additionally, serum anti-PA titers, neutralizing PA antibodies, and the levels of IgA-expressing cells were all comparable with the historical recombinant PA plus aluminum hydroxide vaccine administered s.c. Collectively, development of this strategy for oral delivery of DC-targeted antigens provides a safe and protective vaccine via a bacterial adjuvant that may potentiate mucosal immune responses against deadly pathogens.
Dr. Todd Klaenhammer, 919/515-2972 or firstname.lastname@example.org
Mick Kulikowski | Newswise Science News
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy